✦ LIBER ✦

A phase I, open label, dose-escalating study of the proteasome inhibitor PS-341 (VELCADE¢) in combination with two schedules of trastuzumab, in patients with advanced breast cancer (ABC) that overexpresses HER-2

✍ Scribed by F. Cardoso; Azambuja; C. Bernard; L. Dirix; D. De Becker; S. Bartholomeus; V.D Hondt; H. van de Velde; M. Piccart; A. Awada

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A phase I and pharmacologic study of seq

✍ Cynthia Ma; Sumithra J. Mandrekar; Steven R. Alberts; Gary A. Croghan; Aminah Ja 📂 Article 📅 2006 🏛 Springer 🌐 English ⚖ 310 KB

A phase 2 study of everolimus combined w

✍ Hurvitz, Sara A.; Dalenc, Florence; Campone, Mario; OâRegan, Ruth M.; Tjan-Hei 📂 Article 📅 2013 🏛 Springer US 🌐 English ⚖ 327 KB

The insulin-like growth factor-I recepto

✍ Molife, L R; Fong, P C; Paccagnella, L; Reid, A H M; Shaw, H M; Vidal, L; Arkena 📂 Article 📅 2010 🏛 Nature Publishing Group 🌐 English ⚖ 469 KB

Pharmacokinetic–pharmacodynamic relation

✍ Lionel D Lewis; Bernard F Cole; Paul K Wallace; Jan L Fisher; Mary Waugh; Paul M 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 285 KB

414 POSTER A phase I, open-label, dose e

✍ M.S. Gordon; L.S. Rosen; F. Robert; D.S. Mendelson; D. Kleinzweig; B.J. Adams; C 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 61 KB

Results of two open label Multicentre ph

✍ J.-M. Nabholtz; T. Pienkowski; D. Nothfelt; W. Eiermann; E. Quan; P. Fumoleau; R 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 170 KB